{"slideshow_credits": null, "snippet": "Perjeta, a Genentech drug already approved for late-stage breast cancer, could be used in patients before surgery to remove tumors if the F.D.A. approves it.", "abstract": "Food and Drug Administration advisory committee clears way for first approval of cancer drug that would be used to treat patients before surgery to remove tumors; Perjeta, developed by Genentech, had previously been approved only for treatment of late-stage breast cancer.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/09/13/business/panel-backs-drug-for-early-stage-breast-cancer.html", "lead_paragraph": "Perjeta, a Genentech drug already approved for late-stage breast cancer, could be used in patients before surgery to remove tumors if the F.D.A. approves it.", "headline": {"main": "F.D.A. Panel Backs Pre-Surgery Drug for Breast Cancer", "print_headline": "F.D.A. Panel Backs Pre-Surgery Drug for Breast Cancer"}, "_id": "5233254438f0d8062fddf74b", "word_count": "746", "multimedia": [], "pub_date": "2013-09-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Breast Cancer", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "5"}, {"value": "Cancer", "name": "subject", "is_major": "N", "rank": "7"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Genentech Inc", "name": "organizations", "is_major": "Y", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}